Clinical trials for progressive differentiated thyroid cancer: Patient selection, study design, and recent advances

Thyroid

Volumn 19, Issue 12, 2009, Pages 1393-1400

  Schlumberger, Martin ^a   Sherman, Steven I ^b  

^a INSTITUT NATIONAL DU CANCER   (France)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; DEPSIPEPTIDE; LEVOTHYROXINE; MOTESANIB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; RADIOACTIVE IODINE; RETINOIC ACID; ROSIGLITAZONE; SORAFENIB; SUNITINIB; THYROTROPIN;

ANOREXIA; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISTANT METASTASIS; DRUG EFFICACY; FATIGUE; GENE MUTATION; HORMONAL THERAPY; HUMAN; HYPERTENSION; METHODOLOGY; MOLECULAR THERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; THYROID CANCER; THYROID CARCINOMA; TREATMENT OUTCOME;

BONE NEOPLASMS; CARCINOMA, PAPILLARY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAP KINASE SIGNALING SYSTEM; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 75449115904     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.1603     Document Type: Review

References (65)

1. Schlumberger MJ, Filetti S, Hay ID 2003 Non toxic goiter and thyroid neoplasia. In: Larsen RP, Kronenberg HM, Melmed S, Polonsky KS (eds) Williams' Textbook of Endocrinology, 10th edition. WB Saunders Company, Philadelphia, PA, pp 457-490.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W; The European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur J Endocrinol 154:787-803.
4. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger M 2005 Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and=or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90:5723-5729.
5. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhomou E, Gardet P, Caillou B, Travagli JP, Parmentier C 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55: 794-804. (Pubitemid 15173518)
6. Rouxel A, Hejblum G, Bernier MO, Boelle PY, Menegaux F, Mansour G, Hoang C, Aurengo A, Leenhardt L 2004 Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 89:5362-5368.
7. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, Ito K, Ito K, Tanala S 1999 Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 84:4043-4049.
8. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW 2006 Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91:313-319.
9. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, de Vathaire F, Schlumberger M 2006 Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899.
10. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B 1993 Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34:1626-1631.
11. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID 1995 Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 80:2041-2045.
12. Biondi B, Filetti S, Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1:32-40.
13. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242.
14. Travagli JP, Cailleux AF, Ricard M, Baudin E, Caillou B, Parmentier C, SchlumbergerM1998 Combination of radio-iodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 83:2675-2680.
15. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G 2001 Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568-1573.
16. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216. (Pubitemid 30099779)
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247.
19. Shimaoka K, Schoenfeld DA, de Wys WD, Creech RH, de Conti RA 1985 Randomized trial of Doxorubicin versus Doxorubicin plus Cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160.
20. Williams SD, Birch R, Einhorn LH 1986 Phase II evaluation of Doxorubicin plus Cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70:405-407.
21. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C 1990 Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76:480-483.
22. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, Pinchera A, Pacini F 2002 Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 87:4160-4165.
23. Fagin JA 2004 How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183:249-256.
24. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306.
25. Felsher DW 2008 Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 68:3081-3086.
26. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M 2001 Over-expression and overactivation of Akt in thyroid carcinoma. Cancer Res 61:6105-6111.
27. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G 2000 PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 19:3146-3155.
28. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladany M, Janakiramen M, Solit D, Knauf JA, Tuttle RA, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3-CA, and AKT1. Cancer Res 69:4885-4893.
29. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184.
30. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199-10207.
31. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693. (Pubitemid 41159359)
32. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI 2008 Phosphatidylinositol 3-kinase=Akt and RAS=RAFmitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93:278-284.
33. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with pathological features. Am J Pathol 155: 1967-1976.
34. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A, Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656-658.
35. de la Torre NG, Buley I, Wass JA, Turner HE 2006 Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 13:931-944.
36. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh Qy 2000 Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 128:1059-1065; discussion 1065-1066.
37. Krause DS, van Etten RA 2005 Tyrosine kinase as targets for cancer therapy. N Engl J Med 353:172-187.
38. Santoro M, Carlomagno F 2006 Drug insight: small molecules inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2:42-52.
39. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive, differentiated thyroid cancer. N Engl J Med 359: 31-42.
40. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of Sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
41. Kloos RT, Ringel MD, Knopp MV, Hall NC, Kinbg M, Stevens R, Liang J, Wakely PE Jr., Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
42. Hoftijzer H, Heemstra K, Morreau H, Stokkel M, Corssmit E, Gelderblom AJ, Weijers K, Pereira A, Huijberts M, Kapiteijn E, Romijn J, Smit J 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931.
43. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713.
44. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, Villaflor VM, Siewert Ty, Nichols K Vokes EE 2008 Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26 Suppl:abstract 6025.
45. Bible KC, Smallridge RC, Maples WJ, Molina JR, Menefee ME, Suman VJ, Burton JK, Bieber CC, Ivy SP, Erlichman C 2009 Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol 27 Suppl:15s, abstract 3521.
46. Pacini F, Sherman SI, Schlumberger M, Elisei R, Wirth L, Basholt L, Droz JP, Martins R, Hofmann M, Locati L, Eschenberg M, Stepan D 2007 Exacerbation of postsurgical hypothyroidism during treatment of advanced differentiated (DTC) or medullary (MTC) thyroid carcinoma with AMG 706. Horm Res 68 Suppl 3:29.
47. Cabanillas ME, Waguespack SG, Bronstein Y, Williams M, Feng L, Sherman SI, Busaidy NL 2009 Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): the M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 27 Suppl:15s, abstract 6060.
48. Sherman SI 2009 NCCN practice guidelines for thyroid cancer, version 2009a. Available at www.nccn.org. Accessed June 1, 2009.
49. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM 2007 Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3:260-269.
50. Gruning T, Tiepolt C, Zophel K, BredowJ, Kropp J, FrankeWG 2003 Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? Eur J Endocrinol 148:395-402.
51. Liu YY, Stokkel MP, Morreau HA, Pereira AM, Romijn JA, Smit JW 2008 Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 68:605-609.
52. Su YB, Tuttle RM, Fury M, Ghossein R, Singh B, Herman R, Venkatraman ES, Stambuk H, Robbins R, Pfiste DG 2006 A phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: preliminary toxicity and efficacy experience. J Clin Oncol (ASCO Annu Meet Proc Part I), 24 (18S Suppl): 5554.
53. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, Greenspan FS, Lindsay S, Duh QY, Morita E 2006 A phase II trial of rosiglitazone in patients with thyroglobulinpositive and radioiodine-negative differentiated thyroid cancer. Surgery 140:960-966; discussion 966-967.
54. Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, Abe S, Nakano S, Nishino M, Ishigaki T, Naganawa S 2007 Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 48:889-895.
55. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW 2007 The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 3:112-121.
56. Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, Shankar LK 2009 Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 45:290-299.
57. Hedinger C, Williams ED, Sobin LH Histological typing of thyroid tumours. In: International Histological Classification of Tumours. World Health Organization 1988, volume 11, second edition. Springer-Verlag, Berlin.
58. Volante M, Rapa I, Papotti M 2008 Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues. Endocr Pathol 19:150-155.
59. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring Gl, Pignon JP, Piedbois P 2007 Progressionfree survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218-5224. (Pubitemid 350232253)
60. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P 2000 Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356:373-378.
61. Fleming TR, Rothmann MD, Lu HL 2009 Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 27:2874-2880.
62. Ratain MJ, Sargent DJ 2009 Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 45:275-280.
63. Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS 2009 Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology 76:59-68.
64. Pà ez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231.
65. Ebos JM, Lee CR, Cruz-MunozW, Bjarnason GA, Christensen JG, Kerbel RS 2009 Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239.